C. Skyler Cochrane

C. Skyler Cochrane

Auto-generated profile, based on publicly available information

C. Skyler Cochrane

Department of Biochemistry, Duke University School of Medicine, Durham, NC, 27710, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
JZJinshi Zhao
Jinshi Zhao
CCC. Skyler Cochrane
C. Skyler Cochrane
JNJavaria Najeeb
Javaria Najeeb
DGDavid Gooden
David Gooden
CSCarly Sciandra
Carly Sciandra
PZPei Zhou
Pei Zhou
The UDP-3- O -( R -3-hydroxyacyl)- N -acetylglucosamine deacetylase LpxC is an essential enzyme in the biosynthesis of lipid A, the outer membrane anchor of lipopolysaccharide and lipooligosaccharide in Gram-negative bacteria. The development of LpxC-targeting antibiotics toward clinical therapeutics has been hindered by the limited antibiotic profile of reported non-hydroxamate inhibitors and unexpected cardiovascular toxicity observed in certain hydroxamate and non–hydroxamate-based inhibitors. Here, we report the preclinical characterization of a slow, tight-binding LpxC inhibitor, LPC-233, with low picomolar affinity. The compound is a rapid bactericidal antibiotic, unaffected by established resistance mechanisms to commercial antibiotics, and displays outstanding activity against a wide range of Gram-negative clinical isolates in vitro. It is orally bioavailable and efficiently eliminates infections caused by susceptible and multidrug-resistant Gram-negative bacterial pathogens in murine soft tissue, sepsis, and urinary tract infection models. It displays exceptional in vitro and in vivo safety profiles, with no detectable adverse cardiovascular toxicity in dogs at 100 milligrams per kilogram. These results establish the feasibility of developing oral LpxC-targeting antibiotics for clinical applications.

27 October 2025 in ACS Infectious Diseases
Verified
Journal Article
Closed access
PDPatrick A. Dome
Patrick A. Dome
CCC. Skyler Cochrane
C. Skyler Cochrane
Hannah Joy SwitzerHannah Joy Switzer
Hannah Joy Switzer
HLHyejin Lee
Hyejin Lee
PJPyeonghwa Jeong
Pyeonghwa Jeong
PZPei Zhou
Pei Zhou

20 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlexander A. Mestre
Alexander A. Mestre
YOYunju Oh
Yunju Oh
JWJianli Wu
Jianli Wu
DDDenise Dunn
Denise Dunn
YSYasaman Setayeshpour
Yasaman Setayeshpour
JCJen-Tsan Ashley Chi
Jen-Tsan Ashley Chi
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and contributes to diverse pathologies including ischemia-reperfusion injury and neurodegenerative disorders. Current ferroptosis inhibitors largely function as nonspecific radical-trapping antioxidants, limiting their clinical utility. We previously identified MESH1 as a key regulator of ferroptosis through its NADPH phosphatase activity. Here, we identify 4,5,6,7-tetrabromo-1 H -benzotriazole (TBB) as a small molecule inhibitor of MESH1 with an IC 50 value of 4.7 ± 0.3 µM. X-ray crystallography revealed the molecular determinants of TBB recognition which are corroborated through structure-activity relationships of TBB analogs. TBB protected multiple cell lines against ferroptosis in vitro , and this effect was mitigated by MESH1 knockdown, consistent with on-target activity. Furthermore, TBB reduced neuronal death in an ex vivo brain slice model of Alzheimer’s disease. Collectively, these findings establish TBB as a bona fide small-molecule MESH1 inhibitor that suppresses ferroptosis and establishes MESH1 as a promising therapeutic target. Graphical Depicting mechanism of TBB suppressing ferroptosis through the inhibition of MESH1. Figure Created with Biorender.com

2 June 2023 in ChemMedChem
Verified
Journal Article
Open access
SKSeung‐Hwa Kwak
Seung‐Hwa Kwak
CCC. Skyler Cochrane
C. Skyler Cochrane
JCJae Cho
Jae Cho
PDPatrick A. Dome
Patrick A. Dome
AEAmanda F. Ennis
Amanda F. Ennis
JHJiyong Hong
Jiyong Hong